About Küleon

Our Team

Allen C. Barbieri

CHIEF EXECUTIVE OFFICER

David Gilles

Chief Technical Officer

Jason Greer

CHIEF FINANCIAL OFFICER


Scientific Advisory Board

Peter J. Weiden, M.D.

Christoph Correll, M.D.

Jianmin Duan, Ph.D.


Other Advisors

John McCorvy, Ph.D.

Adam Halberstadt, Ph.D.

Küleon is a drug discovery company focused on developing novel compounds for the targeted treatment of various neuropsychiatric disorders.  We’ve created a proprietary portfolio of serotonin receptor agonists designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved characteristics (low/no hallucinogenic or cardiotoxic liability) when compared to other known serotonergic drugs.